Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 38 Issue 1
Mar.  2020
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2020  >  38(1): 14-17,34

ZHOU Xun, TAN Luojiao, ZHAO Hongyu, GAO Shouhong. Research progress of valproic acid genomics[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 14-17,34. doi: 10.3969/j.issn.1006-0111.201906018
Citation: ZHOU Xun, TAN Luojiao, ZHAO Hongyu, GAO Shouhong. Research progress of valproic acid genomics[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 14-17,34. doi: 10.3969/j.issn.1006-0111.201906018
shu

Research progress of valproic acid genomics

doi: 10.3969/j.issn.1006-0111.201906018
  • 1.

    Department of Pharmacy, Changhai hospital, Naval Medical University, Shanghai 200433, China

  • 2.

    Fourth Comprehensive Support Center, Bureau of Retired Veteran Cadres in Beijing, Garrison District, Beijing 100191, China

  • 3.

    65589 Troops of PLA, Daqing 163712, China

  • 4.

    Department of Pharmacy, Changzheng Hospital, Naval Medical University, Shanghai 200003, China

  • Received Date: 2019-06-10
  • Rev Recd Date: 2019-10-11
  • Valproic acid is a commonly used and broad-spectrum antiepileptic drug in clinical practice with a narrow therapeutic window. Valproic acid has a great individual difference in its metabolism which is influenced by many factors. The gene polymorphism of drug metabolic enzymes is one of the critical factors. Through consulting relevant articles, the affection of genomics and clinical treatment on valproic acid clinical application were reviewed in this paper, which provided a reference for clinical individualized treatment.
  • [1] 张小伟. 新型抗癫痫药物的研究进展[J]. 临床合理用药杂志, 2017, 10(33):180-181
    [2] 陈玲, 苗苗, 刘俊. 癫痫患者丙戊酸血清浓度监测及与临床疗效的关联性分析[J]. 中国医院用药评价与分析, 2015, 15(12):1613-1616
    [3] SONG P G, LIU Y Z, YU X W, et al. Prevalence of epilepsy in China between 1990 and 2015: A systematic review and meta-analysis[J]. J Glob Health,2017,7(2):020706
    [4] TOMSON T, BATTINO D, PERUCCA E. The remarkable story of valproic acid[J]. Lancet Neurol,2016,15(2):141
    [5] 闫秋艳, 朱乐亭, 赵志刚, 等. 233例丙戊酸血药浓度监测结果分析[J]. 中国药师, 2018, 21(2):264-267
    [6] 朱明媚, 景霞, 孙芳, 等. CYP2C9、CYP2A6基因多态性对丙戊酸钠血药浓度的影响[J]. 南京医科大学学报(自然科学版), 2017, 37(1):40-43, 47
    [7] WANG W Z, WU J Z, LI S C, et al. Sodium valproate for epilepsy in rural China: an efficacy and safety assessment in primary care[J]. Epilepsy Res,2012,102(3):201-205
    [8] 王灿, 马虹英, 王方杰, 等. 丙戊酸肝毒性的早期预警及预防研究状况[J]. 中国临床药理学杂志, 2015, 31(2):150-154
    [9] KOUGA T, SHIMBO H, IAI M, et al. Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome[J]. Brain Dev,2015,37(2):243-249
    [10] 沈建玲, 李惠英, 任丹阳, 等. 丙戊酸的相关代谢酶基因多态性研究进展[J]. 海峡药学, 2019, 31(4):100-103
    [11] GHODKE-PURANIK Y, THORN C F, LAMBA J K, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics[J]. Pharmacogenet Genomics,2013,23(4):236-241
    [12] 储小曼, 郭岑, 张丽芳. 丙戊酸的代谢特征与其肝毒性的相关性[J]. 中国医院药学杂志, 2013, 33(19):1611-1614
    [13] DORADO P, LÓPEZ-TORRES E, PEÑAS-LLEDÓ E M, et al. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms[J]. Pharmacogenomics J,2013,13(4):359-361
    [14] SABIN O, TRIFA A P, BRUSTUREAN E, et al. Study of CYP2C9 and CYP2C19 polymorphisms in a Romanian epilepsy population[J]. Human Veterin Med,2013,5(3):77-81
    [15] 韩瑞玲, 李艳, 吴薇. 癫痫患者CYP2C19基因多态性对丙戊酸钠血药浓度的影响[J]. 神经损伤与功能重建, 2015, 10(4):295-297
    [16] 冯亚娟, 周建华, 刘科兰, 等. 丙戊酸代谢相关CYP2C19基因多态性在癫痫患儿体内的分布及治疗个体化研究[J]. 中国实用神经疾病杂志, 2015, 18(5):49-52
    [17] TAN L, YU J T, SUN Y P, et al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients[J]. Clin Neurol Neurosurg,2010,112(4):320-323
    [18] 谭喜莹, 张宇, 王淑云, 等. CYP2C9与CYP2C19基因多态性与癫痫患者丙戊酸血药浓度关系研究[J]. 药学与临床研究, 2011, 19(2):123-126
    [19] 廖清船, 史菁菁, 张永, 等. 细胞色素P450酶2A6、2B6、2C9及2C19基因多态性对丙戊酸钠血药浓度的影响[J]. 中华神经科杂志, 2013, 46(2):82-86
    [20] 孙妍萍, 谭兰, 宋敬卉. CYP2A6基因多态性对丙戊酸钠血药浓度的影响[J]. 中华神经科杂志, 2006, 39(11):745-747
    [21] 谭兰, 郁金泰, 欧江荣, 等. 细胞色素P450等位基因多态性与丙戊酸钠血药浓度的相关性[J]. 临床神经病学杂志, 2009, 22(3):168-171
    [22] 文志鹏, 肖坚, 陈小平. 丙戊酸的药物基因组学研究进展[J]. 中南药学, 2016, 14(5):526-531
    [23] CHATZISTEFANIDIS D, GEORGIOU I, KYRITSIS A P, et al. Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid[J]. Pharmacogenomics,2012,13(9):1055-1071
    [24] MEI S H, FENG W X, ZHU L T, et al. Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model[J]. Eur J Clin Pharmacol,2018,74(8):1029-1036
    [25] 谭喜莹, 张小萍, 邱召娟. UGT1A6基因多态性与癫痫患者丙戊酸血药浓度相关性研究[J]. 药学与临床研究, 2014, 22(4):299-301
    [26] GUO Y J, HU C, HE X J, et al. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy[J]. Drug Metab Pharmacokinet,2012,27(5):536-542
    [27] INOUE K, SUZUKI E, YAZAWA R, et al. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C >T polymorphism on the concentration of valproic acid in pediatric epilepsy patients[J]. Ther Drug Monit,2014,36(3):406-409
    [28] 孙银香, 卓文燕, 林虹, 等. UGT2B7 C802T和G211T基因多态性对癫痫患者丙戊酸代谢的影响[J]. 中国医院药学杂志, 2015, 35(3):216-219
    [29] 马虹英, 张婷, 龚志成, 等. UGT2B7基因多态性对丙戊酸血药浓度的影响[J]. 中南大学学报(医学版), 2013, 38(8):766-772
    [30] SURENDRADOSS J, CHANG T K, ABBOTT F S. Assessment of the role of in situ generated(E)-2, 4-diene-valproic acid in the toxicity of valproic acid and(E)-2-ene-valproic acid in sandwich-cultured rat hepatocytes[J]. Toxicol Appl Pharmacol,2012,264(3):413-422
    [31] 谢新芳, 温燕, 高守红, 等. 丙戊酸钠及其代谢产物的体外肝毒性研究[J]. 药学实践杂志, 2017, 35(1):43-47, 53
    [32] ZHAO M M, ZHANG T, LI G F, et al. Associations of CYP2C9 and CYP2A6 polymorphisms with the concentrations of valproate and its hepatotoxin metabolites and valproate-induced hepatotoxicity[J]. Basic Clin Pharmacol Toxicol,2017,121(2):138-143
    [33] 李新林, 张媞, 周敬凯, 等. CYP2A6基因多态性对丙戊酸肝毒性的影响[C]//第四届全国治疗药物监测学术年会论文集. 长沙, 2014: 44.
    [34] JAFARIAN I, ESKANDARI M R, MASHAYEKHI V, et al. Toxicity of valproic acid in isolated rat liver mitochondria[J]. Toxicol Mech Methods,2013,23(8):617-623
    [35] CHEN Z J, WANG X D, WANG H S, et al. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy[J]. Seizure,2012,21(2):110-117
    [36] SARUWATARI J, DEGUCHI M, YOSHIMORI Y, et al. Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases[J]. Epilepsy Res,2012,99(1-2):183-186
    [37] 陈卓佳, 王雪丁, 王红胜, 等. ACSM 2A和CPT IA基因多态性与丙戊酸所致不良反应的相关性研究[C]. 第十届全国药物和化学异物代谢学术会议暨第三届国际 ISSX/CSSX 联合学术会议论文集, 2012: 232-233.
    [38] 王化明, 赖萍, 谢娟. 用NONMEM法建立癫痫患者丙戊酸群体药代动力学模型[J]. 今日药学, 2012, 22(1):1-6
    [39] JIANG D C, BAI X R, ZHANG Q X, et al. Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling[J]. Eur J Clin Pharmacol,2009,65(12):1187-1193
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(5019) PDF downloads(2674) Cited by()

Related
Proportional views

Research progress of valproic acid genomics

doi: 10.3969/j.issn.1006-0111.201906018
  • 1. Department of Pharmacy, Changhai hospital, Naval Medical University, Shanghai 200433, China
  • 2. Fourth Comprehensive Support Center, Bureau of Retired Veteran Cadres in Beijing, Garrison District, Beijing 100191, China
  • 3. 65589 Troops of PLA, Daqing 163712, China
  • 4. Department of Pharmacy, Changzheng Hospital, Naval Medical University, Shanghai 200003, China
  • Received Date: 2019-06-10
  • Rev Recd Date: 2019-10-11

Abstract: Valproic acid is a commonly used and broad-spectrum antiepileptic drug in clinical practice with a narrow therapeutic window. Valproic acid has a great individual difference in its metabolism which is influenced by many factors. The gene polymorphism of drug metabolic enzymes is one of the critical factors. Through consulting relevant articles, the affection of genomics and clinical treatment on valproic acid clinical application were reviewed in this paper, which provided a reference for clinical individualized treatment.

ZHOU Xun, TAN Luojiao, ZHAO Hongyu, GAO Shouhong. Research progress of valproic acid genomics[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 14-17,34. doi: 10.3969/j.issn.1006-0111.201906018
Citation: ZHOU Xun, TAN Luojiao, ZHAO Hongyu, GAO Shouhong. Research progress of valproic acid genomics[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 14-17,34. doi: 10.3969/j.issn.1006-0111.201906018
shu

    HTML

Reference (39)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return